PBM Patch for Postoperative Pain Relief After Urological Surgery
2026年6月25日 更新者:National Taiwan University Hospital
A Double-blind Randomized Controlled Clinical Study of the PBM Patch for Postoperative Pain Relief After Urological Surgery
This study is a prospective, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy and safety of a photobiomodulation (PBM) patch (Super Vi PBM Patch - Soothing) and an enhanced PBM patch (Super Vi PBM Patch - Soothing EX), compared with a placebo patch, for postoperative pain relief following urological surgery, including nephroureterectomy with bladder cuff resection (NU+BCR) and adrenalectomy (ADRX).
研究概览
地位
尚未招聘
条件
研究类型
介入性
注册 (估计的)
300
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Shih-Chieh Chueh, Attending Physicia / Professor
- 电话号码:62135 +886-2-3123456
- 邮箱:scchueh@ntu.edu.tw
学习地点
-
-
Taipei City
-
Taipei、Taipei City、台湾、100
- National Taiwan University Hospital
-
接触:
- Shih-Chieh Chueh, M.D.
- 电话号码:62135 +886-2-3123456
- 邮箱:scchueh@ntu.edu.tw
-
Taipei、Taipei City、台湾、106
- National Taiwan University Cancer Center
-
接触:
- Wei-Che Wu, M.D.
- 电话号码:+886972652979
- 邮箱:A01827@ntucc.gov.tw
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Patients aged 18 years or older undergoing unilateral nephroureterectomy with bladder cuff excision, or adrenalectomy (tumor size < 3.5 cm).
- Patients who are capable of clear verbal communication.
- Patients who are able to provide written informed consent.
Exclusion Criteria:
- Individuals with photosensitive constitution or those currently using photosensitizing medications.
- Individuals with a known history of severe allergy or contact dermatitis to medical adhesive patches or tapes.
- Patients with severe psychiatric illness or cognitive impairment.
- Long-term or high-dose opioid users.
- Patients utilizing a Patient-Controlled Analgesia (PCA) pump.
- Individuals with severe hepatic insufficiency or active liver disease.
- Vulnerable populations, individuals with restricted legal capacity, or those who are unable or unwilling to undergo clinical evaluations.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Super Vi PBM Patch - Soothing
The Super Vi PBM Patch - Soothing will be applied to the participant immediately upon arrival in the post-anesthesia care unit (PACU) after surgery.
|
A photobiomodulation (PBM) patch designed for postoperative pain relief.
The patch will be applied immediately upon arrival in the post-anesthesia care unit (PACU) after urological surgery.
|
|
实验性的:Super Vi PBM Patch - Soothing EX
The Super Vi PBM Patch - Soothing EX will be applied to the participant immediately upon arrival in the post-anesthesia care unit (PACU) after surgery.
|
A photobiomodulation (PBM) patch designed for postoperative pain relief.
The patch will be applied immediately upon arrival in the post-anesthesia care unit (PACU) after urological surgery.
|
|
安慰剂比较:Placebo Patch
The Placebo Patch will be applied to the participant immediately upon arrival in the post-anesthesia care unit (PACU) after surgery.
|
An placebo patch visually identical to the study patches but without therapeutic photobiomodulation delivery.
The patch will be applied immediately upon arrival in the post-anesthesia care unit (PACU) after urological surgery.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time-Weighted Mean Visual Analogue Scale (VAS) Pain Score at Rest
大体时间:Baseline (preoperatively), and 1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, and 24±2 hours postoperatively
|
The preoperative baseline VAS pain score at rest will be recorded before surgery.
Postoperative VAS pain scores at rest will be assessed at 1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, and 24±2 hours after surgery.
The time-weighted mean VAS pain score at rest (Scale: 0-100 mm; higher scores indicate worse pain) during the first 24 hours postoperatively will be analyzed using a mixed model for repeated measures (MMRM).
Sensitivity analysis will be performed using the area under the curve from baseline to 120 hours (AUC₀-₁₂₀h) with an analysis of covariance (ANCOVA) model.
|
Baseline (preoperatively), and 1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, and 24±2 hours postoperatively
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Total Postoperative Analgesic Consumption
大体时间:Up to 120 hours postoperatively
|
Comparison of the frequency and total dosage of analgesic use among the three groups within 120 hours postoperatively.
Analgesics include non-opioids (e.g., Acetaminophen, NSAIDs) and opioids (e.g., Morphine, Tramadol).
Opioid use will be converted to Morphine Milligram Equivalents (MME) for standardized comparison, in order to evaluate and verify the opioid-sparing effect of the study patch.
|
Up to 120 hours postoperatively
|
|
Proportion of Patients Achieving Patient Acceptable Symptom State (PASS)
大体时间:1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, 24±2 hours, 48±2 hours, 72±2 hours, 96±2 hours, and 120±2 hours postoperatively
|
Proportion of participants in each group achieving Patient Acceptable Symptom State (PASS), defined as a Visual Analogue Scale (VAS) pain score of ≤33 mm (scale: 0-100 mm; higher scores indicate worse pain) at 1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, 24±2 hours, 48±2 hours, 72±2 hours, 96±2 hours, and 120±2 hours postoperatively, used to assess patient satisfaction with pain control.
|
1 hour ±30 minutes, 2±1 hours, 6±2 hours, 12±2 hours, 24±2 hours, 48±2 hours, 72±2 hours, 96±2 hours, and 120±2 hours postoperatively
|
|
Clinical Recovery Progress
大体时间:From end of surgery to hospital discharge, assessed up to 5 days postoperatively
|
Time to first ambulation out of bed and length of postoperative hospital stay will be recorded and compared among the three groups, to evaluate whether patch treatment accelerates the clinical recovery process.
|
From end of surgery to hospital discharge, assessed up to 5 days postoperatively
|
|
Quality of Life Improvement
大体时间:Baseline (preoperative) to 120 hours postoperatively
|
Change in quality of life from preoperative baseline to 120 hours postoperatively, assessed using the Traditional Chinese version of the EQ-5D-5L questionnaire (EuroQol 5-Dimension 5-Level).
Higher index scores indicate better health-related quality of life.
The EQ Visual Analogue Scale (EQ-VAS) will be reported as a supplementary measure, with higher scores indicating better self-rated health.
|
Baseline (preoperative) to 120 hours postoperatively
|
|
Safety Assessment
大体时间:Up to 120 hours postoperatively
|
Detailed recording of all adverse events occurring during the study period, including patch-site skin reactions (e.g., erythema, itching, rash) and analgesic-related side effects (e.g., nausea, vomiting, dizziness).
|
Up to 120 hours postoperatively
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月1日
初级完成 (估计的)
2028年2月28日
研究完成 (估计的)
2028年3月31日
研究注册日期
首次提交
2026年6月18日
首先提交符合 QC 标准的
2026年6月25日
首次发布 (实际的)
2026年6月26日
研究记录更新
最后更新发布 (实际的)
2026年6月26日
上次提交的符合 QC 标准的更新
2026年6月25日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
其他研究编号
- 202603101DINA、202603107DINA
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
未定
IPD 计划说明
It is not yet determined whether individual participant data will be shared with other researchers.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.